3.3 Pharmacogenomics Flashcards
The mechanisms through which genetics may affect drug action:
- Pharmacokinetics, to do with drug absorption, distribution, metabolism and excretion
Transport Proteins
- Move drugs and other substances in and out of cells
- Divided into two types: ____________________
Metabolism
- Phase I (e.g. cytochrome P450)
- Phase II enzymes (e.g. thiopurine methyltransferase)
solute carriers (SLC) & ATP-binding cassette (ABC)
Example of a transport protein and a drug-induced ADR
- ____________ is responsible for the transport of simvastatin into hepatocytes. A variant in the gene encoding ___________is associated with_________________
- A mutation at SNP ______________– (in which the base T is replaced by C) of this gene reduces the transport of simvastatin into cells and leads to higher blood concentration of the drug which likely leads to myopathy
SLCO1B1; SLCO1B1; statin-inducedmyopathy;
rs4149056
Drug metabolism
- When taken into the body, all drugs are either: Excreted (1/4) though the bile or urine Or metabolised (3/4)
- Drug metabolism is classified into phase I and phase II
- Most drugs are metabolised by the cytochrome system, a component of phase I
Cytochromes are electron-carrying mitochondrial proteins
- They are highly conserved ____________________ with a single heme group
- They play a vital role in cellular oxidations in both plants and animals
Cytochrome proteins are classified by the similarity in the gene sequences. They are assigned:
- A family number (e.g., CYP1, CYP2)
- A subfamily letter (e.g., CYP1A, CYP2D)
- Then differentiated by a number for the isoform or individual enzyme (e.g., CYP1A1, CYP2D6)
¾ of drugs are metabolised and ¾ of this is carried out by the cytochrome system Relative importance of the individual cytochromes in drug metabolism: - \_\_\_\_\_\_\_\_\_\_\_ family 46% - \_\_\_\_\_\_\_\_\_ 16% - CYP2C19 12% - CYP2D6 12% - CYP1A family 9% - CYP2B6 2% - CYP2E1 2%
~12kDa proteins consisting of a single 104 amino acid peptide;
CYP3A;
CYP2C9
How cytochrome function may be affected
Genetic variation
- The usual phenotype is referred to as the ____________________
- Genetic variants that affect the function of the gene lead to a poorly functional or non-functional protein
- The phenotype is a poor metaboliser if both copies of the gene are non-functional
- If a person has a copy of a wildtype gene and a mutated gene, he may be an ________________
- If a person has multiple copies of a wildtype gene, he may be a ______________
- Some drugs inhibit cytochrome function E.g. _________________________
Inhibition can occur rapidly - Some drugs induce or potentiate cytochrome function E.g. ______________
Induction takes hours or days
rapid metaboliser;
intermediate metaboliser;
ultrarapid metaboliser
cimetidine, fluconazole, fluoxetine, clarithromycin, (grapefruit juice);
rifampicin, carbamazepine, (chargrilled meat)
Warfarin is metabolised by ____________
- People with the minor allele metabolise the drug more slowly and need a ____________ to reach the therapeutic effect
CYP2C9;
lower dose
Clopidogrel, an anti-platelet agent, is an inactive pro-drug that is converted to the active form by _____________
- It is found that slow metabolisers do worse than rapid metabolisers in the secondary prevention of ischaemic heart disease
CYP2C19
Codeine is also a pro-drug that is converted to ___________ by __________
- Slow metabolisers require a ___________ dose of the drug to achieve the same analgesic effects as rapid metabolisers
morphine;
CYP2D6;
larger
Tamoxifen is an inactive drug that is converted both by ________________ to the active form _______________
- Poor metabolisers may not benefit from the protection against breast cancer recurrence
CYP2D6 and CYP3A4/5;
endoxifen
Phase II metabolising proteins
Phase II proteins conjugate the phase I metabolites, other intermediates, or the parent compound, for ______________
Phase II proteins include:
_____________________
renal or biliary excretion;
- Glutathione S transferases (GSTs)
- Thiopurine methyltransferase (TMPT)
- UDP glycurosyltransferases (UGT)
- N-acetyltransferases (NAT)
- Glutathione S transferases (GSTs)
- NADH quinone oxidases.
Thiopurine methyltransferase
- Some patients develop _____________ when prescribed azathioprine
- Polymorphism in the gene that encodes the enzyme thiopurine methyltransferase (TPMT) is an important determinant of this adverse effect
- Azathioprine is used in the treatment of ________________________
- Patients with normal TPMT activity or normal genotype may receive the normal dose of azathioprine (such as 50 mg daily)
- Intermediate metabolisers should receive ____________________
- Poor metabolisers should use an alternate drug; if none are available, azathioprine must be used very cautiously (_______________) with close monitoring
life-threatening leucopaenia;
cancers, inflammatory bowel disease and systemic lupus erythematosus;
30-80% of the usual dose;
10% of the dose and thrice weekly dosing
Hardy-Weinberg equilibrium
- The Hardy–Weinberg principle states that _____________________________
- It was first proposed to dispel the thinking that the dominant allele will gradually displace the recessive one in succeeding generations
- Therefore the proportion of people with certain conditions, such as thalassaemia and colour blindness, will remain fairly stable in subsequent generations provided there is no mutation, migration, or selection
allele and genotype frequencies in a population will remain constant from generation to generation in the absence of other evolutionary influences
Azathioprine and NUDT15
- Asian populations have a lower frequency of poor TPMT activity but also experience leucopaenia with thiopurine treatment
- The_______________ is more important in determining the adverse effect of thiopurine in Asians
- The NUDT15 gene product is also responsible for the metabolism of the thiopurines
NUDT15 gene
Warfarin pharmacogenetics
- Warfarin is an anticoagulant that is still widely used
- Warfarin is a chiral drug that is marketed as a racemate consisting of equal amounts of R- and S-enantiomers
- The _______________ is more potent
- Warfarin accounted for more drug-related emergency room visits in the US than any others
- Warfarin is metabolised by ________
- Its target is ____________
- Variants in the genes encoding these proteins affect the therapeutic dose of warfarin
- _____________ metabolises vitamin K
- Variants of its gene have a small effect on the warfarin dose
S-enantiomer;
CYP2C9;
VKORC1;
CYP4F2
Pharmacogenetics of warfarin in Singapore
- Patients carrying the minor allele in
_______________ genes require lower doses of warfarin
- Proportionately more Chinese and Malay carry the CC allele of VKORC1 gene than Indians. Which explains why patients of these two ethnicities require lower doses of warfarin
CYP2C9 and VKORC1 ;
Human leucocyte antigen and severe cutaneous allergic reactions
In the mid 2000’s, HLA subtypes were discovered to be associated with severe cutaneous reactions to drugs, namely:
- HLA-B*1502 and _____________
- HLA-B*5701 and ____________
- HLA-B*5801 and ______________
The mechanism behind the association has been worked out only for one.
- Abacavir interferes with _____________ to the cleft of HLA-B*5701
- So that self-antigens could be presented
- Leading to immune response against many of the patient’s own tissues
carbamazepine;
abacavir;
allopurinol;
binding of peptides